Six weeks after Clovis voluntarily discontinued its third-line use of ovarian cancer drug Rubraca in the United States for safety reasons, Europe’s Committee for Medi...

Eisai is shutting down an oncology venture for good. Continuing the recent CDMO expansion spree, Wuxi Biologics is plotting a $1.4 billion R&D and manufacturing s...

Biogen is trying to escape the dark Aduhelm cloud hanging over its Alzheimer's disease drug launch. So far, the launch has triggered layoffs, a CEO switch and much mo...

Shortly after the FDA delayed a decision for Novartis and BeiGene’s tislelizumab in previously treated esophageal squamous cell carcinoma (ESCC), the company is scrap...

In a rare miss for the drug, Merck & Co.’s immuno-oncology cash cow Keytruda has flunked a study in a tough-to-treat form of cancer. Alongside chemoradiation ...

A Texas federal court has determined that Daiichi Sankyo willfully infringed a Seagen patent in creating its breast cancer drug Enhertu. But it will not enhance a $41...

The pipeline of personalized medicines for blood cancers is fit to burst, GlobalData warns. Branding the development landscape “oversaturated,” the data and analy...

After a three-month delay this spring, Incyte has clinched its second dermatology nod for Opzelura. And this time, it’s a historic one. Late Monday, the FDA gave ...

While reimbursement and education challenges persist, drugmakers like Eli Lilly and Novo Nordisk are poised to unlock a global obesity market that could be worth more...

In yet another Teva opioid settlement, the company has agreed to pay $24.8 million over 13 years, plus provide $20 million worth of Narcan over 10 years, to resolve i...